MiR-204 regulates type 1 IP3R/Ca2+ axis to control vascular smooth muscle cell contractility and blood pressure: Potential role of the gut microbiome
MiR-204 regulates type 1 IP3R/Ca2+ axis to control vascular smooth muscle cell contractility and blood pressure: Potential role of the gut microbiome
批准号:
10291115
负责人:
Modar O. Kassan
金额:
$45.64万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-09-01 至 2025-06-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Hypertension is the most prevalent cardiovascular disorder worldwide. Deregulation of vascular
smooth muscle cell (VSMC) contraction is a final common pathway in hypertension. Intracellular
calcium (Ca2+) is a trigger and key determinant of VSMC contraction. Vascular smooth muscle
cytosolic Ca2+ concentration is tightly regulated by Ca2+ influx and efflux from the extracellular
space and from intracellular stores, most notably the sarcoplasmic reticulum. Inositol 1,4,5-
trisphosphate (IP3) through its receptors (IP3R) controls Ca2+ release form the sarcoplasmic
reticulum into the cytoplasm.
Hypertension is a multi-system disease. Disruption of homeostatic mechanisms in distant
organs can affect vascular tone. As one example, bacteria that inhabit the gut (gut microbiome)
can modulate blood pressure. Normotensive animals become hypertensive when transplanted
with gut microbiota from hypertensive animals, and vice versa. Furthermore, hypertension in
humans is associated with specific alterations in gut microbial diversity, lending credence to the
premise that a change in gut microbial load and diversity (dysbiosis) contributes to the
pathogenesis of hypertension. Our preliminary data shows that dysbiosis in mice caused by
broad-spectrum antibiotics leads to hypercontractility of blood vessels and associated
upregulation of IP3R1. In addition, we have evidence that broad-spectrum antibiotics
downregulate expression of miR-204, a microbiome-sensitive microRNA, in vascular smooth
muscle cells. Moreover, miR-204 targets IP3R1, and mice with global deletion of miR-204 are
susceptible to developing hypertension. We therefore hypothesize that miR-204 is a key
regulator of VSMC contractility, and its downregulation due to gut microbial dysbiosis promotes
hypertension.
This application will examine the role of miR-204 in regulating VSMC Ca2+ and explore the
mechanisms by which it does so. It will use mice with deletion of miR-204 and IP3R1 in VSMC,
and state-of-the-art methodologies to assess Ca2+ flux in cells and in vessels of live animals.
Using these unique tools, and with the assembled expertise, it will determine if miR-204 controls
blood pressure, VSMC Ca2+ homeostasis and VSMC contraction via IP3R1. In addition, it will
blaze a trail connecting the gut microbiome and regulation of vascular tone, by determining if gut
microbial dysbiosis disrupts VSMC Ca2+ homeostasis, and promotes hypertension through
downregulation of miR-204. Information gained from this work will be a vertical advancement in
the field of hypertension research.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MiR-204 regulates type 1 IP3R/Ca2+ axis to control vascular smooth muscle cell contractility and blood pressure: Potential role of the gut microbiome
-
批准号:10248555
-
项目类别:
-
资助金额:$46.93万
-
财政年份:2020
-
负责人:Modar O. Kassan
-
依托单位:
MiR-204 regulates type 1 IP3R/Ca2+ axis to control vascular smooth muscle cell contractility and blood pressure: Potential role of the gut microbiome
-
批准号:10447756
-
项目类别:
-
资助金额:$46.93万
-
财政年份:2020
-
负责人:Modar O. Kassan
-
依托单位:
国内基金
海外基金
登录
查看更多内容
外泌体lncRNA TUG1通过miR-204-5p/FOXC1信号通路靶向调控HUVECs促进肝母细胞瘤血管生成的机制研究
-
批准号:2026JJ81317
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:袁妙贤
-
依托单位:
母乳外泌体源 miR-204-3p 通过 IL1R1 调控肠黏膜屏障对新生儿坏死性小肠结肠炎的干预及机制研究
-
批准号:2026JJ80525
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:陈振江
-
依托单位:
miR204-5p通过AKAP1/MTP18调控线粒体融合/分裂参与胸主动脉夹层动脉瘤的机制研究
-
批准号:JCZRYB202500200
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
脂肪干细胞外泌体递送circPpm1d调控miRNA-204-3p/GPR157网络抑制肺泡巨噬细胞焦亡:慢阻肺治疗新机制
-
批准号:2024Y9410
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:朱志兴
-
依托单位:
人参皂苷 Rg3 促进肿瘤细胞外泌体释放
miR-204 调控胰腺癌血管生成拟态的机制研
究
-
批准号:Z24H280019
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:林胜璋
-
依托单位:
IFI204/ARMCX3/Caspase-11靶向促进巨噬细胞焦亡在水凝胶粘合剂系统清除创伤性骨髓炎中胞内菌的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:胡岩君
-
依托单位:
负载MUR仿生脂质体粘合剂靶向调控荷菌巨噬细胞IFI204/ARMCX3/Caspase-11焦亡抑制创伤性骨髓炎发生的机制研究
-
批准号:82372421
-
项目类别:面上项目
-
资助金额:48万元
-
批准年份:2023
-
负责人:胡岩君
-
依托单位:
miR-204-5p靶向SKI调控髓核细胞凋亡在椎间盘退变中的机制研究
-
批准号:82360435
-
项目类别:地区科学基金项目
-
资助金额:32万元
-
批准年份:2023
-
负责人:张海鸿
-
依托单位:
褪黑素预处理增加脐带间充质干细胞来源外泌体中miR-204改善压力负荷性心衰的机制研究
-
批准号:CSTB2023NSCQ-MSX1041
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2023
-
负责人:汪浩
-
依托单位:
乳腺癌细胞分泌的外泌体miR-204通过诱导白色脂肪组织瘦素的产生促进恶液质发生的机制探究
-
批准号:--
-
项目类别:--
-
资助金额:30万元
-
批准年份:2022
-
负责人:闫卫
-
依托单位: